Esperion Q1 net loss narrows to $25.2 million; product sales rise to $43.4 million

• Esperion Therapeutics posted a net loss of USD 25.2 million, narrowing from USD 40.5 million a year earlier.
• Net sales rose 24.3% to USD 43.4 million, supported by prescription growth volumes of NEXLETOL and NEXLIZET.
• Loss from operations narrowed to USD 6.6 million, while research and development expense fell to USD 9 million.
• Collaboration revenue increased to USD 36.7 million on higher royalty sales growth in partner territories, while interest expense edged up to USD 19.8 million.
• Completed Corstasis acquisition on April 2 with USD 75 million upfront cash consideration, adding Enbumyst, first FDA-approved nasal spray loop diuretic; merger with Parent signed May 1 is expected to close in third quarter of 2026 with per-share cash consideration plus a CVR tied to up to USD 100 million of contingent payments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-032870), on May 08, 2026, and is solely responsible for the information contained therein.